Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay
Recruitment status was Recruiting
Currently, drugs commonly used for antiplatelet are aspirin and clopidogrel when encountering stroke or coronary heart disease. In this study, we would use VASP assay and thromboelastograph with platelet mapping assay kit to evaluate the antiplatelet resistance in general population and the relationship between clopidogrel and proton pump inhibitor.
|Study Design:||Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Screening
|Official Title:||Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping™ Assay|
- Comparison of the antiplatelet drug response apparently shown in TEG & Platelet mapping assay [ Time Frame: 6 months ] [ Designated as safety issue: No ]
|Study Start Date:||May 2008|
|Estimated Study Completion Date:||October 2010|
|Estimated Primary Completion Date:||October 2010 (Final data collection date for primary outcome measure)|
Experimental: Clopidogrel and proton pump inhibitors
all participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.
Drug: Clopidogrel and proton pump inhibitors
baseline detection --> clopidogrel 75 mg PO QD for 1 week --> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week -->
1 week washout --> aspirin 100mg PO QD for 1 week
This study intent is to search the standard to diagnose of the antiplatelet drug resistance and to discover the prevalence of drug resistance in Taiwanese population in Taiwan. The trial will enroll at least 30 healthy people after fulfilling the investigation questionnaire. All the participants will receive antiplatelet drugs in two separate period and measured the efficacy by VASP assay and thromboelastograph with platelet mapping assay. The health volunteer will receive clopidogrel and different types of proton pump inhibitor to see the interference of antiplatelet efficacy between each drug.
|Contact: Fu-Tien Chiang, MD, PhD||886-2-23123456 ext firstname.lastname@example.org|
|Contact: Jen-Kuang Lee, MD||886-2-23123456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Taipei, Taiwan, 100|
|Contact: Fu-Tien Chiang, MD, PhD 886-2-23123456 ext 62150 firstname.lastname@example.org|
|Contact: Jen-Kuang Lee, MD 886-2-23123456 ext 62394 email@example.com|
|Principal Investigator:||Fu-Tien Chiang, MD, Phd||National Taiwan University Hospital|